Status:
COMPLETED
Effectiveness of BNT162b2 Formulations Using State Vaccine Registry and Insurance Claims Data
Lead Sponsor:
Pfizer
Conditions:
SARS-CoV-2
COVID-19 Vaccines
Eligibility:
All Genders
Brief Summary
The primary purpose of this study is to learn about how well different versions of the Pfizer-BioNTech COVID-19 vaccine (called BNT162b2) work at preventing death, severe COVID-19 that requires a trip...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- People with at least one year of pharmacy and medical enrollment in HealthVerity prior to vaccine availability
- State of California or Louisiana resident for at least one year
- Exclusion criteria:
- People currently pregnant,
- Individuals with discrepancies in sex and/or year of birth between HealthVerity claims and California/Louisiana immunization registry datasets
- A diagnosis of COVID-19 in any setting ≤ 90 days prior to start of study or receipt COVID-19 vaccine ≤ 90 days prior to start of study.
Exclusion
Key Trial Info
Start Date :
September 11 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 31 2024
Estimated Enrollment :
19853610 Patients enrolled
Trial Details
Trial ID
NCT06199934
Start Date
September 11 2023
End Date
July 31 2024
Last Update
September 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Global Headquarters
New York, New York, United States, 10001